The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery

Angiology

Volumn 66, Issue 2, 2015, Pages 128-135

  Kouvelos, George N ^a   Arnaoutoglou, Eleni M ^a   Milionis, Haralampos J ^a   Raikou, Vaia D ^b   Papa, Nektario ^a   Matsagkas, Miltiadis I ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cholesterol; Estimated glomerular filtration rate; Ezetimibe; Kidney; Rosuvastatin; Surgery

Indexed keywords

CREATININE; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; AZETIDINE DERIVATIVE; BIOLOGICAL MARKER; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ACUTE HEART INFARCTION; ADD ON THERAPY; ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG EFFECT; ELECTIVE SURGERY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MONOTHERAPY; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; VASCULAR SURGERY; ADVERSE EFFECTS; ALBUMINURIA; BLOOD; COMPARATIVE STUDY; DRUG EFFECTS; DYSLIPIDEMIAS; GREECE; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; PILOT STUDY; TIME; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; DYSLIPIDEMIAS; ELECTIVE SURGICAL PROCEDURES; FEMALE; FLUOROBENZENES; GLOMERULAR FILTRATION RATE; GREECE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRIMIDINES; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES;

EID: 84925581780     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319713519492     Document Type: Article

References (29)

1. Welten GM, Chonchol M, Schouten O, et al. Statin use is associated with early recovery of kidney injury after vascular surgery and improved long-term outcome. Nephrol Dial Transplant. 2008;23(12):3867-3873.
2. Welten GM, Chonchol M, Hoeks SE, et al. Statin therapy is associated with improved outcomes in vascular surgery patients with renal impairment. Am Heart J. 2007;154(5):954-961.
3. Patel VI, Lancaster RT, Mukhopadhyay S, et al. Impact of chronic kidney disease on outcomes after abdominal aortic aneurysm repair. J Vasc Surg. 2012;56(5):1206-1213.
4. Poldermans D, Bax JJ, Boersma E, et al. Guidelines for preoperative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the task force for preoperative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol. 2010;27(2):92-137.
5. Schouten O, Boersma E, Hoeks SE, et al. Dutch echocardiographic cardiac risk evaluation applying stress echocardiography study group. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med. 2009;361(10):980-989.
6. Schouten O, Kok NF, Boersma E, et al. Effects of statins on renal function after aortic cross clamping during major vascular surgery. Am J Cardiol. 2006;97(9):1383-1385.
7. Moulakakis KG, Matoussevitch V, Borgonio A, Gawenda M, Brunkwall J. Evidence that statins protect renal function during endovascular repair of AAAs. Eur J Vasc Endovasc Surg. 2010; 40(5):608-615.
8. Kouvelos GN, Arnaoutoglou EM, Matsagkas MI, et al. Effects of Rosuvastatin With or Without Ezetimibe on Clinical Outcomes in Patients Undergoing Elective Vascular Surgery: Results of a Pilot Study. J Cardiovasc Pharmacol Ther. 2013; 18(1):5-12.
9. Sarigianni M, Katsiki N, Mikhailidis DP. Ezetimibe in diabetes: more than cholesterol lowering? Curr Med Res Opin. 2010; 26(10):2517-2520.
10. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin. 2007;23(8):2009-2026.
11. Nakamura T, Sato E, Fujiwara N, et al. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol independent manner. Pharmacol Res. 2010;61(1):58-61.
12. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9): 604-612.
13. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1-S266.
14. Grundy SM, Cleeman JI, Merz CN, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-239.
15. Alnaeb ME, Youssef F, Mikhailidis DP, Hamilton G. Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease. Angiology. 2006;57(1):65-71.
16. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57(7):728-734.
17. Adult Treatment Panel III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
18. Mikhailidis DP, Athyros VG. Acute kidney injury: short-term statin therapy for prevention of contrast-induced AKI. Nat Rev Nephrol. 2014;10(1):8-9.
19. Campese VM, Ku E, Bigazzi R, Bianchi S. Do HMG-CoA reductase inhibitors improve kidney function? the saga continues. J Nephrol. 2011;24(5):550-553.
20. Kalaitzidis RG, Elisaf MS. The role of statins in chronic kidney disease. Am J Nephrol. 2011;34(3):195-202.
21. Kostapanos MS, Milionis HJ, Gazi I, Kostara C, Bairaktari ET, Elisaf M. Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia. J Clin Pharmacol. 2006;46(11):1337-1343.
22. Gorriz JL, Martinez Castelao A. Proteinuria: detection and role in native renal disease progression. Transplant Rev (Orlando) 2012; 26(1):3-13.
23. Brantsma AH, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT, PREVEND Study Group. Extended prognostic value of urinary albumin excretion for cardiovascular events. J Am Soc Nephrol. 2008;19(9):1785-1791.
24. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia. 1994;37(5):511-516.
25. Eijkelkamp WB, Zhang Z, Remuzzi G, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007; 18(5):1540-1546.
26. Shepherd J, Kastelein JJ, Bittner V, et al; Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2(6):1131-1139.
27. Migdalis I, Efthimiadis A, Pappas S, Alexopoulos D, Vlasserou F, Mikhailidis DP. Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Curr Med Res Opin. 2009;25(10): 2571-2576.
28. Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin. 2007;23(9):2183-2192.
29. Nakamura T, Sato E, Fujiwara N, et al. Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res. 2009;60(6):525-528.